These are my thoughts and positions,
1. Appears that NVAX has opportunity for breakout as pennant matures
2. Price is trending healthily above 200 EMA.Price is also above and respecting the 50 EMA like they're in a long term committed relationship celebrating Valentine's day.
3. Notice the mid term higher lows signifying...
While Novavax has some positives, it is not a good candidate for new money. Novavax's two marquee programs, RSV F for maternal vaccination and NanoFlu are not doing particularly well, as they are getting delayed.
RSV F for maternal vaccination is now in Phase 3, but many investors are wondering if it's a viable drug. Even if Novavax successfully meets the...
NVAX looks like it may continue up. IT has a couple candles that I have circled that show bullish power- the hammer and then the huge gap up to close in the red. This consolidation seems to be building up to something.
This is my second bullish swing trade on NVAX in a week. The first trade ended with a small gain, I exited the trade early because earnings were the next day and I didn't want to hold through earnings.
I entered the trade later in the day on Thursday. After a big pullback early Thursday NVAX recovered nicely so I entered at $2.05. NVAX looked pretty strong on...
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
NVAX
